These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1622128)

  • 1. Circulating mucins as tumor markers in ovarian cancer (review).
    Devine PL; McGuckin MA; Ward BG
    Anticancer Res; 1992; 12(3):709-17. PubMed ID: 1622128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer.
    Devine PL; McGuckin MA; Ramm LE; Harada H; Ward BG
    Cancer Biochem Biophys; 1993 Sep; 13(4):221-38. PubMed ID: 8521372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
    Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
    Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of monoclonal antibody OC 125 in gynecological oncology].
    Wu AR; Wang EY; Wang XX; Jia XH; Li L
    Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].
    Chen DX; Li FQ
    Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):84-5, 123-4. PubMed ID: 2364796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
    Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
    Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
    Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S
    Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays.
    Davelaar EM; Schutter EM; von Mensdorff-Pouilly S; van Kamp GJ; Verstraeten RA; Kenemans P
    Ann Clin Biochem; 2003 Nov; 40(Pt 6):663-73. PubMed ID: 14629806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
    Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tumor marker--screening for gynecological cancer; personal experience. Utility of tumor markers in screening of ovarian cancer].
    Kimura E; Kobayashi S; Terashima Y
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2443-50. PubMed ID: 2260879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship between tumor markers and clinical symptoms in ovarian cancer].
    Yakushiji M; Nishimura H
    Rinsho Byori; 1992 Apr; 40(4):354-8. PubMed ID: 1593760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
    Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
    Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
    Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis of ovarian tumor by measuring tumor markers].
    Fukatsu T; Nakashima N; Takeuchi J
    Rinsho Byori; 1992 Feb; 40(2):133-8. PubMed ID: 1583785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serodiagnostic tests by factor analysis and stepwise discriminating analysis with tumor markers for the detection of ovarian cancer].
    Kobayashi H; Sumimoto K; Terao T; Kawashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1903-10. PubMed ID: 2480396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of galactosyltransferase associated with tumor (GAT), a new tumor marker for ovarian cancer--with special reference to the discrimination between ovarian cancer and endometriosis].
    Nozawa S; Udagawa Y; Ito K; Nishimura H; Yakushiji M; Shiota M; Noda K; Yajima M; Ohkura H; Murae M
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):507-16. PubMed ID: 8129392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
    Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
    Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.